TIDMCPT TIDMEKF TIDMYGEN
RNS Number : 1867H
Concepta PLC
02 December 2020
Concepta PLC
("Concepta" or the "Company")
Launch of genomic testing service MyHealthChecked
First test available will be for the detection of COVID-19
Proposed change of name to MyHealthChecked Plc
Concepta PLC (AIM: CPT), the personalised healthcare company,
announces the launch of its DNA testing service, following the
recent acquisition of The Genome Store. The testing service will be
launched today under the new MyHealthChecked (TM) brand and the
first test swab kit available will be a fast and reliable direct to
consumer COVID-19 lab-based PCR test available to the UK public via
a new ecommerce website.
The MyHealthChecked(TM) COVID-19 testing service will use the
Clarigene(R) SARS-CoV-2 test supplied by Yourgene Health plc (AIM:
YGEN) and the PrimeStore(R) MTM sample collection device supplied
by EKF Diagnostic Holdings plc (AIM: EKF). The MyHealthChecked(TM)
testing service allows samples to be quickly and conveniently taken
at home using simple nasal collection swabs which are then sent via
free postage for processing using established laboratory-based DNA
and RNA detection methods.
The newly acquired team has delivered the launch of this
COVID-19 testing service to an efficient timescale, enabling an
awareness drive to the public ahead of the Christmas period at a
time when members of the public are making holiday plans. The
Company expects to launch a number of DNA tests covering a range of
female and male wellness, food intolerance and lifestyle testing,
and further develop a pipeline of tests from Q1 2021.
MyHealthChecked (TM) will offer consumers a range of simple to use
DNA tests across key healthcare areas, and target pricing
affordably to improve accessibility for the public.
Penny McCormick, Chief Executive Officer of Concepta plc, said:
"As our pipeline development continues and we invest in our plans
to build a sustainable, long term business, we're proud to be
delivering on this short-term opportunity with a high quality,
highly accurate coronavirus swab kit and testing service. Our
priority is to look beyond the pandemic with a range of affordable,
meaningful at-home test kits, but it would be remiss of us - now
with the expertise and operational channel in-house - not to make
this kit available to the public."
As the government welcomes news on the future arrival of
vaccines, the requirement for at home testing kits is expected to
continue. Last week the Transport Secretary announced a new testing
scheme from 15 December for people travelling into England from
overseas destinations, advising that the purchase of a private test
and a negative coronavirus result could reduce quarantine periods
by more than half.
Ms McCormick commented: "The government is providing clear
guidelines and instructions regarding international travel, and the
meeting of familial and friendship groups over Christmas, and
people are sensibly deciding to what level they wish to operate
within that framework. We fully support the government's testing
programme, whilst providing a solution for those who wish to test
independently for requirements like travel, or for personal
reasons."
Proposed change of name to MyHealthChecked Plc
In addition, the Company also confirms that it will change its
name to MyHealthChecked (TM) Plc. Trading in the Company's shares
on the AIM market of the London Stock Exchange under the new name
is expected to take effect in due course and the Company's stock
exchange ticker is also expected to change from CPT to MHC. The
Company will announce when this is effected. At that time the
Company's website will change to:
www.myhealthcheckedplc.com
Related Party Transactions
The entering into an agreement to use the Clarigene(R)
SARS-CoV-2 test as supplied by Yourgene Health plc, of which both
Adam Reynolds (Chairman) and Lyn Rees (Non-Executive Director) are
Directors, has been treated as a related party transaction. Product
pricing for the agreement has been prepared on an arm's-length
basis and there is no minimum volume requirement. Having consulted
with SPARK Advisory Partners Limited, the Independent Directors
(those directors other than Messrs Reynolds and Rees) consider that
the terms of the agreement are fair and reasonable insofar as
Shareholders are concerned.
In addition, initial purchase orders (of GBP16,500) have been
placed with EKF Diagnostic Holdings plc ("EKF") for PrimeStore(R)
MTM sample collection devices. Adam Reynolds is also a Director of
EKF and this order has been treated as a related party transaction.
Product pricing for the agreement has been prepared on an
arm's-length basis and there is no minimum volume requirement.
Having consulted with SPARK Advisory Partners Limited, the
Independent Directors (those directors other than Mr Reynolds)
consider that the terms of the order are fair and reasonable
insofar as Shareholders are concerned.
Concepta plc www.conceptaplc.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Maddy Kennedy, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Novum Securities (Joint Broker) Tel: +44 (0)20 7399 9400
Colin Rowbury
Oberon Capital Ltd (Joint Broker) Tel: +44 (0)203 179 5344
Mike Seabrook mikeseabrook@oberoninvestments.com
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com
Relations)
Paul McManus Mob: +44(0)7980 541 893
About the Clarigene(TM) SARS-CoV-2 test
The Clarigene(TM) SARS-CoV-2 CE-IVD test is a RT-qPCR
("real-time quantitative polymerase chain reaction") assay which
detects the presence of SARS CoV-2 viral RNA*. The assay uses two
viral RNA targets which are SARS-CoV-2 specific preventing cross
reactivity and providing a more reliable result. Clinical
validation of the test has shown >99.9% accuracy with no false
positive or false negative results. Additional studies have shown
100% repeatability data and an average >99.7%
reproducibility.
About the PrimeStore MTM COVID-19 sample collection device
The PrimeStore MTM sample collection device deactivates the
SARS-CoV-2 virus and stabilises the RNA for transport with no
requirement for cold storage. In a recent study published by Public
Health England PrimeStore MTM was the only commercially available
CE-marked and Food & Drug Administration ("FDA") cleared
transport media.
About Concepta PLC ( www.conceptaplc.com )
Concepta PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company with two diverse, customer-facing at-home
testing brands in its portfolio:
MyHealthChecked is the umbrella brand of a range of at-home DNA
and RNA tests, now in development following the recent acquisition
of The Genome Store. The tests will be made available on line, and
would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a
change in mindset as customers become more familiar with the
concept of accessible healthcare in the growing at home testing kit
market with a focus on accessibility at the right price, led by
UK-based experts.
Mylo targets the personalized mobile health market, with a
primary focus on hormone testing and increasing a woman's chances
of naturally getting pregnant, and providing insight to unexplained
infertility. MYLO is a CE-marked IVD expected to be beneficial to
users who have been unable to conceive after 6 months of trying.
This highly motivated target group of women won't typically be
offered medical intervention until after 12 months of
unsuccessfully trying to conceive, with IVF not usually offered
until after two years of trying to conceive. Research indicates
couples start to take positive action ahead of this time typically
with little medical support to help them do so.
MYLO is currently the UK's only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin ("hCG") hormone level during
pregnancy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUARBRRBUURAA
(END) Dow Jones Newswires
December 02, 2020 02:00 ET (07:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Jan 2024 to Jan 2025
